# A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A

> **NCT04683406** · PHASE3 · COMPLETED · sponsor: **Guangdong Raynovent Biotech Co., Ltd** · enrollment: 750 (actual)

## Conditions studied

- Influenza A

## Interventions

- **DRUG:** ZSP1273 600 mg
- **DRUG:** Placebo to Oseltamivir
- **DRUG:** Oseltamivir(oral)
- **DRUG:** Placebo to ZSP1273

## Key facts

- **NCT ID:** NCT04683406
- **Lead sponsor:** Guangdong Raynovent Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-28
- **Primary completion:** 2023-04-01
- **Final completion:** 2023-05-16
- **Target enrollment:** 750 (ACTUAL)
- **Last updated:** 2023-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04683406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04683406, "A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04683406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*